首页> 外文期刊>Journal of hypertension >Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
【24h】

Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).

机译:长期抗高血压治疗期间颈动脉内膜中层厚度和动脉粥样硬化斑块的绝对和相对变化:欧洲拉西地平动脉粥样硬化研究(ELSA)的进一步结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: In ELSA, a randomized, double-blind trial in 2334 hypertensives, 4-year antihypertensive treatment with lacidipine slowed down progression of carotid atherosclerosis significantly more than atenolol treatment. To avoid bias, the primary outcome was measured blindly at study-end on a randomized sequence of scans, but measurements were limited to the four far walls of common carotids and bifurcations (CBMmax) and to one of each couple of duplicate scans recorded yearly. OBJECTIVES AND METHODS: Secondary outcomes included measurements made on all duplicate scans of both near and far walls, not only of common carotids and bifurcations, but also of internal carotids (12 walls). These measurements were made blindly during the 4-year study, shortly after recording. To avoid possible readers' drift or bias, 250 duplicate baseline scans were re-read at yearly intervals (longitudinal on-line quality control) and a correction factor calculated. RESULTS: Measurements during the 4-year study showed a trend toward decreased values, with the lacidipine effect significantly greater than the atenolol one. A trend toward lower values was also observed in the longitudinal quality control of baseline scans. After applying a correction factor calculated from this longitudinal control, all measurements no longer decreased with time, but significantly increased, with progression being significantly smaller in lacidipine than in atenolol patients. Corrected values were quite similar to those calculated on measurements carried out at study-end. CONCLUSION: The relative benefit of lacidipine over atenolol could be measured precisely by reading scans either during the study or at study-end. However, absolute treatment-related changes (progression versus regression) cannot safely be judged by readings made during a long-term study, unless a longitudinal quality control of readings is performed.
机译:背景:在ELSA中,一项在2334个高血压患者中进行的随机双盲试验显示,拉西地平4年的降压治疗比阿替洛尔治疗更能减缓颈动脉粥样硬化的发展。为避免偏倚,主要结果在研究结束时以随机扫描顺序进行盲测量,但测量仅限于颈总动脉和分支的四个远端壁(CBMmax)以及每年记录的每两次重复扫描中的一个。目的和方法:次要结果包括对近壁和远壁的所有重复扫描进行的测量,不仅对常见的颈动脉和分叉,而且对内部的颈动脉(12壁)进行了测量。记录后不久,在为期4年的研究期间盲目进行了这些测量。为了避免读者可能出现的漂移或偏倚,每隔一年(纵向在线质量控制)重新读取250次重复的基线扫描,并计算校正因子。结果:在为期4年的研究中,测量结果表明数值呈下降趋势,拉米地平的作用明显大于阿替洛尔。在基线扫描的纵向质量控制中也观察到了向较低值的趋势。在应用从该纵向对照算出的校正因子后,所有测量值均不再随时间减少,而是显着增加,拉西平的进展显着小于阿替洛尔患者。校正后的值与研究结束时计算得出的值非常相似。结论:拉西地平相对于阿替洛尔的相对获益可以通过在研究期间或研究结束时进行阅读扫描来精确测量。但是,除非进行纵向质量控制读数,否则不能通过长期研究期间的读数安全地判断与治疗绝对相关的变化(进展与消退)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号